stockrowAbivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Return on equity
Abivax SA Sponsored ADR's return on equity over the twelve months to 30 June 2026 was −249.8%, down 113.7 percentage points from fiscal 2025 (−136.1%). Over the past ten years it has ranged from −452.0% (fiscal 2020) to 0.00% (fiscal 2018); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −136.1% | 12.89 |
| FY2024 | −149.0% | (3.41) |
| FY2023 | −145.6% | 172.08 |
| FY2022 | −317.6% | (63.29) |
| FY2021 | −254.3% | 197.65 |
| FY2020 | −452.0% | (303.18) |
| FY2019 | −148.8% | (148.81) |
| FY2018 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| CORT Corcept Therapeutics Incorporated compare | 21.7% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| PRAX Praxis Precision Medicines, Inc. compare | −38.9% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −64.9% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −167.5% |
| AXSM Axsome Therapeutics, Inc. compare | −175.6% |
| ABVX Abivax SA Sponsored ADR | −249.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)